Thiamacare contains 10 mg/ml thiamazole, which is double the concentration of Thyronorm, for a lower dose volume.
Animalcare highlights research which shows that 87.4% of owners prefer liquid medications for their cat1, and that cats find liquid presentations more palatable2.
James Beaumont from Animalcare said: "With the lowest dose volume available, we believe Thiamacare will make the medical management of this condition easier through improved cat acceptance and better owner compliance."
Thiamacare's dosing syringe is marked with a single scale in 1.25 mg increments to facilitate precise dosing in response to total T4 measurement values. The scale does not need converting when switching from other brands or formulations.
Animalcare has developed a range of supporting materials to encourage the use of Thiamacare as the preferred choice for feline hyperthyroid medical management. They include social posts and a post-prescription leaflet to help veterinary teams support owners, particularly through the stabilisation phase post-diagnosis.
A short webinar offering top tips for treating feline hyperthyroidism from feline Specialist Dr Caney will also be available later in October. These resources will all be available at www.the-pac.co.uk.
References
Genitrix has launched Libromide, the first licensed formulation of potassium bromide for the treatment of canine epilepsy, following what the company believes to be the largest ever trial of dogs suffering from epilepsy.
Genitrix says the availability, for the first time, of a licensed formulation of potassium bromide should give veterinary surgeons and pet owners the reassurance that the rigorous authorisation process provides. It ensures, for instance, that the product has been developed especially for dogs and that it is manufactured in accordance with EU regulations. It also ensures that the product has been extensively and independently trialled, proven to be efficacious without adverse reactions, and that the necessary pharmacovigilance is in place to support it.
The company also says that the availability of a licensed product paves the way for more comprehensive information to be provided to veterinary surgeons on the use of potassium bromide in treating seizures. The Veterinary Medicines Directorate (VMD) imposes restrictions on educational materials supplied by manufacturers of unlicensed products, an approach which has created a 'knowledge gap' among many veterinary surgeons in general practice, according to some canine epilepsy experts.
Libromide tablets are intended for use in epileptic dogs which have already commenced therapy with Phenobarbital. Phenobarbital acts to increase the effects of the GABA inhibitory neurotransmitter in the central nervous system. Potassium bromide is synergistic with Phenobarbital and raises the seizure threshold level in epileptic dogs.
Libromide is classified as POM-V and will be available in 325 mg tablets in packs of 100 and 500 tablets.
Rodolfo Cappello DVM PhD DipECVN MRCVS, RCVS and European Specialist in Neurology and Neurosurgery, Head of Neurology Services at North Downs Specialist Referrals, Surrey, said: "I've been successfully using potassium bromide for the treatment of epilepsy in dogs for over 15 years. The main problem has been that it's not been licensed as a medicine. With the launch of Libromide, potassium bromide finally achieves the status of an approved pharmaceutical. We will now be able to monitor quality, efficacy and side effects which will enable us to offer a more professional approach to the treatment of seizures."
Howard Wilder, founder and managing director of Genitrix, added: "Canine epilepsy is an all too common disease with estimates suggesting it affects four in every hundred dogs in the UK. It's also an illness which is not well enough understood with the lack of up to date information available to veterinary surgeons being a contributing factor.
We felt there was an opportunity to bring a licensed product to market and have invested hundreds of thousands of pounds in the process of development and trialling Libromide. We're delighted to make it available to veterinary professionals and hope its launch will be the first step in improving treatment approaches for this distressing disease."
Veterinary surgeons have named their top new veterinary products of 2012 in a survey carried out by CM Research.
As part of the research, 343 vets working in UK practice were asked what they considered to be the best new product of 2012. Their answers were unprompted, and they were only allowed to mention one product or service. For this reason, some vets voted for products that were launched earlier than 2012. The full results were as follows:
Hill's y/dAn iodine restrictive hyperthyroid management food launched by Hill's Pet Nutrition in May 2012 won with an overwhelming 31% of the votes. www.hillspet.co.uk
Cardalis (CEVA Animal Health)Launched towards the end of 2012, CEVA's combined ACE inhibitor / spirolactone for heart failure in dogs scored a creditable 9.6% of mentions. www.ceva.co.uk
Seresto (Bayer Animal Health)Bayer's 8-month flea and tick collar came third with 6% of the votes. www.seresto.com.
Caninsulin Vetpen from MSDLaunched in July 2012, this new insulin delivery pen for Caninsulin is designed to improving dosing accuracy, consistency and ease of use. The user-friendly pen design is said to improve initial pet owner acceptance and on-going compliance.
Atopica Cat (Novartis Animal Health)Novartis launched Atopica Cat, an oral version of its treatment for chronic allergic dermatitis, at the start of 2012. www.itchfreepet.co.uk
Comfortis (Elanco)Launched in 2011, Comfortis is a novel oral flea adulticide for dogs which kills adult fleas rapidly for a month. www.comfortis.com
Nobivac Myxo RHD (MSD)The first vaccine to combine 12 months protection against both myxomatosis and rabbit haemorrhagic disease within a single inoculation. It is a non-adjuvanted vaccine which, according to MSD, delivers greater simplicity of protocol and enhanced disease protection.
Cimalgex (Vétoquinol)Launched towards the end of 2011, Vetoquinol's 2nd generation Cox-2 inhibitor is said by the company to be very well tolerated, have an excellent efficacy profile and be very easy to use, meaning that Cimalgex allows veterinary patients to benefit from pain relief in situations where clinicians would have been worried about the risks versus the benefits of prescribing a NSAID for pain management.
Activyl (MSD)MSD's novel flea spot-on is the first to work by bioactivation, only becoming an insecticide after being ingested by the flea, thus minimising owner's exposure to insecticides. Said to be effective against the other stages of the flea life cycle, too. www.activyl.co.uk
RevitaCAM (Abbott)RevitaCAM is the first and only veterinary NSAID (meloxicam) with oromucousal delivery. www.revitacam.co.uk.
Metacam for cats (Boehringer Ingelheim)Boehringer extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size in July. www.metacam.co.uk.
Zuprevo (MSD)MSD's antibiotic to combat bovine respiratory disease (BRD) was launched in the third quarter of 2011. www.zuprevo.com
V-Gel (Docsinnovent)V-gel was the first ever species-specific supraglottic airway device (pictured top right), currently available for cats and rabbits. Billed as the latest ground breaking technology for a safer anaesthesia, easier breathing and avoiding damage to the throat and trachea; a safer alternative to ET tubes. www.docsinnovent.com
Onsior (Novartis Animal Health)The tissue-selective oral and injectable Cox-2 inhibiting NSAID from Novartis was actually launched back in 2009.
Certifect (Merial)Merial's flea and tick spot-on for dogs was launched by Ray Mears in the UK in February 2012. www.certifect.co.uk
Calmex (VetPlus)Somewhat controversial when it made its first appearance in 2011, Calmex is a feed to help dogs and cats that may experience behavioural problems as a result of their environment or situations that may cause anxiety or fear. More info.
Comfortan (Dechra)The first licensed methadone for dogs was launched by Eurovet towards the end of 2011, before it was acquired by Dechra in May 2012. www.dechra.co.uk
Hill's Vet EssentialsHill's vet-exclusive petfood range is designed to meet essential dietary needs at every life stage. More info.
Trocoxil (Pfizer)Trocoxil, Pfizer's NSAID for canine osteoarthritis was remarkable for its once monthly dosage regime, when launched back in 2009.
VerafloxBayer launched its next generation fluoroquinolone antimicrobial for bacterial infections in cats and dogs at the end of 2011
YumoveYumove is a joint support supplement from Lintbells, containing glucosamine and chondroitin. More information.
The clinic will offer referrals in orthopaedics, internal medicine, soft tissue surgery, neurology and advanced imaging from a team which includes Rory Bell, an RCVS and European Recognised Specialist in Internal Medicine, and Jonathan Bell, an EBVS and RCVS Specialist in Small Animal Surgery.
The practice says it has some of the most advanced equipment in Europe, including a Siemens 128 slice CT scanner and a Siemens 1.5T Aera MRI scanner. The clinic also has three environmentally-controlled theatres, with CT and MRI scanning capabilities.
Dr Stuart Cooke BVetMed CertSAS MRCVS, one of Swift Referrals founders said: “We’re delighted to launch Swift Referrals, and would like to thank everyone who helped us get here. We are proud to be able to say that we house some of the most advanced equipment in the continent, from the very best advanced imaging machines, to specialist treatment and aftercare rooms. We also have some of the most skilled veterinary experts operating in them, day in and day out. Our clinicians are leaders in their field of expertise, with years of experience and very advanced training."
For more information: www.swiftreferrals.co.uk/.
The plan is designed to help mimic the way cats eat in the wild and so provide them with both physical and mental stimulation. It also encourages cats to hunt, explore, climb and play – activities which boost cats’ positive behaviour and wellbeing.
Developed by feline behaviour specialist Dr. Sarah Ellis and Dr. Lizzie Rowe at International Cat Care, the plan is also designed to help to prevent overeating and promote a balance between energy intake and energy output, in order to avoid weight gain, as well as encouraging weight loss in overweight cats.
It is estimated that there are 10 million pet cats in the UK1 and the charity points to data which suggests that 39 – 52% of them are overweight or obese2,3, something which is a major health and welfare issue4-9, and can ultimately lead to early death10.
The charity says research shows that current feeding practices are contributing to this obesity epidemic, with a number of factors associated with a cat’s modern lifestyle leading to overeating. For example, most cats need little or no exertion to obtain their food, making it more likely that the calories they take in through eating will outweigh the calories they use up through exercise (leading to weight gain). Furthermore, the way we feed our cats generally does not match the lifestyle they were designed for, resulting in a lack of mental stimulation and reduced opportunity to express natural, instinctive hunting behaviours. This can lead to boredom, apathy, anxiety, frustration and stress in cats, resulting in reduced wellbeing and potentially the development of problem behaviours.
Sarah said: "By making a few simple changes to the way we feed our cats, we can help them to live longer, healthier and happier lives."
The plan recommends:
A detailed version of the feeding plan, along with the full report behind the development of the plan, can be found on International Cat Care’s website:
https://icatcare.org/advice/general-care/keeping-your-cat-healthy/feeding-your-cat-or-kitten
A short version of the feeding plan can also be found there.
The Mayor of Loughton, Councillor Philip Abraham, officially opened the Vets4Pets Loughton veterinary surgery inside Pets at Home at the Epping Forest Shopping Park, before enjoying a guided tour of the bright and modern facility.
Cheryl, who stars in the BBC’s children’s TV show The Pet Factor, said: "It’s fantastic to be able to open the doors to Vets4Pets Loughton and reach a landmark number of practices for the group.
"The opening event gave us chance to meet new clients, and welcome them to the practice."
Cheryl qualified in 2009 and is also a joint venture partner at Vets4Pets Chadwell and Newbury Park in Ilford.
Nick, who qualified in 2008, is also joint venture partner at Newbury Park, Romford, Beckton and Dagenham.
Nick said: "I have always been interested in caring for pets and have several dogs and cats at home.
"I love being a veterinary nurse and I’m delighted to have another opportunity from Vets4Pets to open my fifth practice.
"Once again the process to open a practice has been easy and we’ve had brilliant support on all aspects from Vets4Pets.
"I’m now looking forward to welcoming pets and their owners to Vets4Pets Loughton and providing the highest standard of veterinary care to the area’s pets."
The new practice will create five new jobs, with two vets, veterinary nurse, two pet care assistants and a receptionist.
Chief executive of the Pets at Home Vet Group, Andrei Balta, said: "Cheryl and Nick are two great advocates for the veterinary profession and we’re delighted they are part of the group.
"Wherever we have opened, pet owners have responded enthusiastically to our state-of-the-art practices and convenient opening hours.
"The joint venture model we operate across our practices provides the support vets and vet nurses need to run their businesses.
"It allows them to focus on what they really love, looking after the health of animals, while the support team helps with other areas including marketing, HR and business strategy."
Merial has announced the launch of Oncept IL-2, the first veterinary immunotherapeutic product in Europe for the management of cancer in pets.
Described by the company as a true breakthrough in the field of veterinary oncology, Oncept IL-2 is an adjunct immunotherapy for feline fibrosarcoma.
Merial says the product is based on recombinant canarypox vector technology it developed collaboratively with veterinary oncologists, and which is used in several of its vaccines, including PUREVAX FeLV and PUREVAX Rabies.
Oncept IL-2 is indicated for cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement, in order to reduce the risk of relapse and to increase the relapse-free interval. It should be used in addition to surgery and radiotherapy.
Kevin Whelan, Merial's Technical Manager said: "Following injection around the tumour surgery site, the recombinant canarypox vector virus enters the cat's cells, which then produce interleukin-2. The presence of this cytokine stimulates an anti-tumour immune response by a variety of mechanisms, including the induction of T-lymphocytes and natural killer cells."
In a field efficacy trial, a treatment course with Oncept IL-2 (consisting of 6 subcutaneous administrations in the tumour bed over a 7-week period), as an adjunct to surgery and radiotherapy, was shown to significantly reduce the risk of relapse and to increase the time to relapse.
The product is available in packs of 6 doses, which is sufficient for a treatment course. Please contact your local Merial Territory Manager for further information or email oncept@merial.com
The RCVS Disciplinary Committee has suspended a London-based veterinary surgeon from the Register for six months, having found that her falsification of clinical records amounted to serious professional misconduct.
At the two-day hearing, Dr Nicola Ersilova was charged with, and admitted to, three separate incidences of false and dishonest clinical record keeping following her treatment of a collapsed cat, whilst working at Vets Now in Thamesmead, London.
The Committee heard how Dr Ersilova had suspected that Lafite the cat, belonging to Mr Yingzhan Xiao, had been poisoned, so administered fluids and treated her with Lidocaine. A lay colleague, who was assisting with the treatment, subsequently observed Dr Ersilova standing staring at the cat, which had stopped breathing, then leaving the room to go and speak to Mr Xiao. The lay colleague's evidence confirmed to the Committee that Lafite's heart was still beating at this point, and that Dr Ersilova was then heard telling Mr Xiao that Lafite had died while being treated. The lay colleague later discovered that Dr Ersilova had listed calcium gluconate on Mr Xiao's bill and not Lidocaine and, when she questioned the entry, Dr Ersilova told her she was worried about getting into trouble if she had listed Lidocaine.
Whilst reporting these irregularities to the senior veterinary surgeon at Vets Now, the lay colleague noticed that Dr Ersilova had also written "CPR unsuccessful" in the notes, although she was certain CPR (cardiopulmonary resuscitation) had not been attempted.
During a subsequent Vets Now investigation, Dr Ersilova admitted adding this false information concerning Lidocaine, calcium gluconate and CPR, saying during interview that she was aware it was serious professional misconduct and that she was prepared to take the consequences. Vets Now reported the matter to the RCVS.
The Committee considered that all evidence before it fully supported the charges against Dr Ersilova, that her conduct was clearly dishonest, and that her actions were inexcusable, especially for someone as experienced as she was. It stated that a veterinary surgeon's duty to make only truthful and accurate records was so manifest and well known to veterinary surgeons that there could be no real excuse to make such false, misleading and dishonest entries.
The Committee highlighted the comment by Dr Ersilova that she knew she had done something wrong but did not expect her colleague to report her, as providing no explanation, or excuse, for doing something which she knew to be wrong.
A number of submissions were made to the Committee in mitigation, including that Dr Ersilova had admitted her dishonesty to both her employers and the Committee; had an otherwise unblemished record over 22 years of practice; had received no immediate financial gain by her actions; and, did not cause any animal suffering.
Accepting these submissions, the Committee nevertheless felt it needed to balance them against other factors. Dr Ersilova's decision to falsify the records was premeditated and had not been taken without an opportunity for full reflection. There were numerous entries in the RCVS Code of Professional Conduct that highlighted the importance of professional integrity and accuracy, and, given the importance which the Code attached to the duty of veterinary surgeons to be truthful and honest in all their dealings with their clients, the Committee found Dr Ersilova's conduct to be "most reprehensible".
Speaking on behalf of the Disciplinary Committee, its Vice-Chairman, Professor Sheila Crispin, said: "It is of great importance that the public should be able to retain confidence in the honesty and integrity of members of the profession. Both the public and other members of the profession must be entitled to rely on the truthfulness of what a veterinary surgeon has written in the clinical records of any animal [they have] treated.
"It is [our] decision that the sanction of suspension adequately reflects the seriousness of the [Dr Ersilova's] conduct. The sanction imposed is ... the most appropriate to inform the profession how seriously such dishonest conduct will be taken, because such conduct clearly brings the profession into disrepute and ... cannot and will not be tolerated."
The Committee then concluded that the least period of suspension that could be justified was one of six months.
Vets Now has published a response to the RCVS DC ruling in which Munhuwepasi Chikosi, a locum working for the company, was struck off for delaying an emergency OOH home visit.
The response is available in full here: http://www.vets-now.com/news/?item=4191
Neuro orthopaedic veterinary surgeon Noel Fitzpatrick has been having a busy old time: hot on the heels of his world-first procedure to implant a prosthetic hip and femur in an American Bulldog comes the news that he has now fitted a cat with titanium prosthetic paws in another world-first.
Oscar the cat was minding his own business, basking in the late summer sun, when a passing combine harvester chopped off his hind paws.
Unlucky.
However, Oscar's luck turned when his veterinary surgeon, Peter Howarth from St Saviour in Jersey, referred owners Kate and Mike Nolan to Fitzpatrick Referrals to investigate the possibility of giving Oscar a pair of prosthetic paws.
Kate said: "We had to do a lot of soul-searching and our main concern has always been whether this operation would be in Oscar's best interests and would give him a better quality of life". Having decided it would, the Nolans asked Noel to go ahead. And so he came to give the two-year-old cat a pair of new artificial feet in a single, three-hour surgical procedure - something he says has never been done before by any team anywhere in the world.
The revolutionary design of the feet uses custom-made implants to 'peg' the ankle to the foot and mimics the way in which deer antler bone grows through skin. These pegs, or ITAPs (intraosseous transcutaneous amputation prosthetics), were first developed by a team from University College London led by Professor Gordon Blunn, Head of the Centre for Bio-Medical Engineering at UCL's Institute of Orthopaedics and Musculoskeletal Science. Working in partnership with UCL, Fitzpatrick has pioneered the use of these weight-bearing prosthetic implants.
During the operation, the veterinary surgical team had to insert the ITAPs by drilling into one of the ankle bones in each of the back legs - an extremely delicate feat, which could have fractured the ankle joint before the procedure had even begun, and even more challenging because it had to be performed twice. These artificial implants which are attached to the bone at an amputation site are coated with hydroxyapatite, which encourages bone cells to grow onto the metal. The skin then grows over the special umbrella at the end of the ITAP to form a resilient seal against bacteria and potentially fatal infections. The ITAP itself protrudes through the bone and skin, allowing the custom-built artifical paws to be attached securely. Click here to see x-rays and other case photos in the VetSurgeon media gallery.
Following successful surgery in November last year, the focus of the veterinary team has turned to the slow process of rehabilitation and helping Oscar to learn to walk again - firstly using external scaffolding anchored to the tibia to protect the new implants until the ITAPs integrated into the bone and the skin grew onto the ITAP. Remarkably Oscar was trying to stand within a day of the operation and despite some problems with infection that had to be overcome, in less than four months Oscar could stand and bear weight equally on all four limbs. He has since been fitted with a series of prototype new paws to ensure the best possible long term fit.
What makes this procedure so complicated is that Oscar's feet were severed at the junction of the tarsus and metatarsus. Noel said: "The real revolution with Oscar is because we have put a piece of metal and a flange into which skin grows into an extremely tight bone, with very narrow tolerances in the region of nanometres, rather than millimetres. We have then successfully managed to get the bone and skin to grow into the implant and we have developed an exoprosthesis that allows this implant to work as a see-saw on the bottom of an animal's limbs to give him effectively normal gait. Oscar can now run and jump about as cats should do.
Noel Fitzpatrick and the team at Fitzpatrick Referrals are the focus of a new six part documentary series: The Bionic Vet to be broadcast on BBC 1 at 10.45 pm every Wednesday starting on 30 June 2010. The programmes will focus on the multi million pound state-of-the-art vet practice in Surrey as well as the ways in which Noel is pioneering revolutionary new surgical techniques.
Ms Gatehouse faced two charges, the first being that she inaccurately assured another veterinary surgeon that she had vaccinated a horse against influenza and tetanus when she had not, and she subsequently failed to undertake adequate checks to confirm whether she had done so.
The second charge was that she later made a false entry in the same horse’s clinical records to cover up her previous inaccurate statement.
Ms Gatehouse admitted the facts alleged in relation to both charges and also admitted that in relation to the second charge she was guilty of disgraceful conduct in a professional respect.
The Committee, having heard submissions from Counsel for the RCVS and Ms Gatehouse found her guilty of disgraceful conduct in relation to the first charge.
Under the first charge the Committee found that she had breached the RCVS Code of Professional Conduct for Veterinary Surgeons by not keeping clear, accurate and detailed clinical and client records, and by acting in a manner that was likely to undermine public trust in the profession.
They also considered that her falsehood was unpremeditated, and that the decision was made in a moment of panic. Ultimately, however, by claiming the horse was vaccinated to another veterinary surgeon and not taking the necessary steps to confirm this, she failed to put the welfare of the animal first, potentially endangering it and any other horses it came into contact with, as well as potentially jeopardising the position of the veterinary surgeon she confirmed it to.
Having found Ms Gatehouse guilty of serious professional misconduct in relation to both parts of the charge the Committee then considered its sanction against her. In mitigation the Committee considered the fact that she had been in practice for 22 years without any untoward conduct, the testimony of three witnesses who attested to her being an honest and trustworthy practitioner, and the fact that Ms Gatehouse was in a troublesome relationship with the complainant until June 2014 which led her to be reluctant to contact him to correct her initial confirmation.
In summing up Stuart Drummond, Chair of the Committee, said: "The Committee has considers that it is material to have regard to the general emotional state to which the Respondent was reduced by the controlling and debilitating conduct of her then partner when they were living together and the consequential loss of self-esteem and ability to stand up to him and his demands. The deleterious effect of an abusive relationship lingers after such a relationship ends.
"Taking into account this knowledge, the Committee considers that the period of suspension that would, in other circumstances, be entirely merited, can properly be reduced in this instance to reflect the fact that this veterinary surgeon would not have acted as she did during this period but for the fact that her judgement was adversely affected by her experience at the hands of her then former partner.
"The decision is that, whilst it is necessary, in order sufficiently to protect animals and the wider public interest, to impose a period of suspension from practice, that period can be reduced to one of two months. In so concluding the Committee wishes to make it clear that this decision reflects the special features of this case."
Ms Gatehouse can choose to appeal the decision after a period of 28 days.
The new maternity policy will offer enhancement at 100% of full pay for 10 weeks, and 50% of full pay for a further 10 weeks, without any clawback provision should mothers decide not to return to CVS after their leave.
As part of the Time To Change Pledge, CVS will submit a plan for introducing evidence-based interventions and policy to help its employees work in ways that promote positive mental wellbeing.
CVS's plan includes the appointment of 250 Wellbeing Champions who will be trained in first aid for mental health. The company also plans to roll out further training on managing stress and mental health issues for line managers in 2020.
Richard, pictured right, said: "We are proud to be the first major veterinary employer to sign the Time to Change Pledge. The CVS wellbeing working party have made much progress in the last 12 months delivering our plan which has been formalised through participating in the Time to Change pledge.
"We recognise that the pressures in our industry are significant and unique, and that there’s more work to do. We remain committed as a company and wellbeing working party to changing the way we all think and act about mental health in the workplace for the better."
Andrew Montgomery, veterinary adviser for MSD Animal Health, says this is a very positive outcome for the industry: "It is estimated that 90% of UK herds have been exposed to bovine viral diarrhoea1 (BVD), costing the UK cattle industry up to £61 million each year2."
The new Summary of Product Characteristics for Bovilis BVD states that following primary immunisation, consisting of two vaccinations given 4 weeks apart to cattle over the age of 8 months, and a further vaccination 6 months after this, revaccinations can be given at up to 12 month intervals.
Andrew said: "The fundamental principle of control, is to identify and remove persistently infected (PI) animals from a herd, and stop PIs being created using a trusted and proven vaccine.
"Providing primary immunisation has been finalised 4 weeks before the start of gestation, Bovilis BVD is licensed to protect the foetus against transplacental infection, preventing the creation of a PI calf which is hugely significant for BVD control.
"The convenience of being able to vaccinate on a herd level without having to assess pregnant animals on a case-by-case basis provides the flexibility to tailor vaccination schedules to the farm system, which for many vets and farmers comes as a convenient solution."
MSD says Bovilis BVD also has the advantage of not interfering with antigen ELISA or PCR testing and can be jointly administered with other routine vaccines.
For example, Bovilis BVD can be mixed and administered with Bovilis® IBR Marker Live when given as a booster dose to cattle from 15 months of age, or can be administered on the same day as Leptavoid-H in cattle from 8 months of age.
For further information, refer to the product data sheets at www.noahcompendium.co.uk and SPCs and/or speak to your local MSD Animal Health area manager.
Virbac has launched of Bovigen Scour, an emulsion for injection into cattle which reduces the severity of diarrhoea caused by bovine rotavirus, bovine coronavirus and enteropathogenic E.coli F5 (K99).
Bovigen Scour works by actively immunising pregnant cows and heifers and providing passive immunity to their calves via colostrum. According to the company, the vaccine also helps to reduce the shedding of virus by calves infected with bovine rotavirus and coronavirus.
Virbac says a key benefit of Bovigen Scour is the vaccination protocol which offers a large window for injection, making it easier for vaccination planning. The primary course is administered in two shots, with first dose between 12 and 5 weeks before calving and the booster 3 weeks later. The annual booster is then due between 12 and 3 weeks before calving is expected. The vaccine is presented in two sizes: 15ml (5 doses) and 90ml (30 doses). The dosage per cow is 3 ml and the withdrawal time is nil in milk.
Virbac Large Animal Product Manager Brigitte Goasduf MRCVS said: "Bovigen Scour offers farmers flexibility and ease of use. The flexibility it gives in terms of scheduling the primary course and booster is particularly important and is highly relevant for beef cattle farmers as it can be difficult to know exactly when a cow is likely to calve and it is vital not to miss the vaccination window.
"Bovigen Scour is also convenient to give because of the small volume of emulsion and because the injection is given intramuscularly. Its launch extends our large animal vaccine range, which includes Gudair, for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (Map)."
Boehringer Ingelheim Vetmedica has launched Buscopan 20mg/ml injection, an antispasmodic treatment for use in cases of equine colic, and an aid to the symptomatic treatment of calf scour.
A sister product to Buscopan Compositum which contains both an antispasmodic and a non-steroidal component, Buscopan 20 contains only the antispasmodic component - hyoscine butylbromide.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without an NSAID for use in horses and cattle. I'm pleased to say that it's finally here and I'm sure that Buscopan 20 will be a very welcome addition to the armoury of both equine and cattle practitioners."
Buscopan 20 is supplied in a 50ml multi-dose bottle, and is available in veterinary wholesalers now.
For further information, please call 01344 746959.
Briar House Veterinary Surgery achieved 944 top rated reviews over the past 12 months, with pet-owners leaving comments such as 'Absolutely fantastic would recommend to everybody', 'Brilliant all round service' and 'You can tell that they love and care for the animals as much as the owners do'.
Briar House said: "We are absolutely delighted to win the Vet Help Direct Best UK Vet award, it means so much to the practice and team. We would like to say a big thank you to all of our wonderful clients and patients for taking the time to review your experience with us. We are very proud of our surgery, so it is a pleasure to receive such positive feedback from our clients."
Silver and Bronze Awards were achieved by Vets 1 Group and St Anne’s Veterinary Group, with 350 and 330 top reviews respectively. Other winners included Lamond Veterinary Clinic (Best Scottish Vet), Bridgnorth Veterinary Centre (Best Small Practice), Penmellyn Equine Vets (Best Equine Vet), Medivet The Vets Hendon (Best London Vet), The Mobile Vet (Best Mobile Vet), St James Veterinary Group (Best Welsh Vet) and Cedar Grove Veterinary Clinic (Best Northern Ireland Vet).
The full list of results, including those making the Top 25, can be viewed here.
Susie Samuel, Managing Director of VetHelpDirect said: "Reviews are a great way to find out what your clients really think, offering insight into where you are excelling or where there could be improvements. They are also excellent for building your online reputation, which will give you the competitive edge over other local practices, ultimately leading to new clients.
"More than ever, people are using review sites to seek 'real' opinions, in fact a recent survey in the US found that 97% of consumers read online reviews for local businesses, and 85% of consumers trust online reviews as much as personal recommendation.1 While these numbers may not truly reflect the situation in the UK veterinary industry, they are quite staggering, and signal that reviews and online reputation is going to become increasingly more important.
For more information about building your online reputation, contact Vet Help Direct on 0845 4961 204 or email: info@vethelpdirect.com.
Reference:
The new rules will make it illegal to sell puppies younger than eight weeks and require anyone breeding and selling three or more litters of puppies a year to apply for a formal licence.
Those needing a licence, including online sellers, will also be required to display their permit in any advertising, and to give owners information about the five welfare needs that owners must meet under the Animal Welfare Act.
The penalty for breaking the new law will be an unlimited fine and/or up to six months in prison.
The plans also cover how pet shops, boarding houses and riding stables are licensed, introducing a single 'animal activities licence' to improve the process and make enforcement easier.
Environment Secretary Andrea Leadsom said: "Everyone who owns a pet or is looking to introduce one into their life will want to know that the animal has had the very best start to life. Yet for thousands of puppies born each year to irresponsible breeders, from smaller operations to larger puppy farms, their first weeks are spent in cramped and squalid conditions without the care and attention they need. That is why we are cracking down on the worst offenders by strengthening the dog breeding licence and giving councils the power they need to take action.
With more and more pet sales now taking place on the internet, it’s right that this market is subject to the same strict licensing criteria as other breeders and pet shops so that consumers are not misled. The plans announced today will help people choosing new family pets to be confident the animals have been properly bred and cared for from birth and are ready to move safely to their new homes.
Gudrun Ravetz, President of the British Veterinary Association, said: "This is a significant step in the right direction to improve the welfare of puppies and dogs in the UK, an issue our members are extremely concerned about as increasing numbers of poorly bred puppies are brought into veterinary practices.
"Poorly bred and badly socialised puppies cause terrible health and welfare problems for dogs so it is right that Defra has made irresponsible dog breeding a priority. We particularly welcome the move to make the sale of a puppy under eight weeks illegal, the reduction in the number of litters bred requiring a formal breeder’s licence, and the moves towards a single animal activities licence. In the future we would also like to see that anyone breeding from a dog should be required to register with their local authority.
"For these new measures to work in practice local authorities must have the necessary resources and support to fully enforce the legislation, supported by local veterinary expertise.
"We hope the new legislation will encourage owners to stop and think about where they’re getting their puppies from to tackle irresponsible breeding both at home and abroad. Prospective owners should do their homework and always use the puppy contract and information pack to make sure they ask breeders the right questions for a happy, healthy puppy."
The Kennel Club and Dogs Trust have welcomed the announcement.
Dogs Trust Veterinary Director, Paula Boyden said: "As the UK’s largest dog welfare charity, Dogs Trust welcomes the Government’s review of animal establishments licensing in England and the range of measures it sets out.
"We are particularly pleased that it will be illegal to sell a puppy below the age of 8 weeks and that there will be tighter licensing rules which will require sellers of pets to display their licence when advertising. We also applaud the move towards a risk based single licensing system which will incorporate those breeders that have gained UKAS approval rather than exempting them.
We believe that Local Authority Inspectors need support to enforce these tighter licensing rules. As such, moves to mandate the use of Model Conditions and for inspectors to be offered training and standards to be set is most welcome."
ECM, a French manufacturer of ultrasound devices, has launched Exago, a new mobile veterinary ultrasound device which the company says is particularly suited for use with horses and pets.
ECM says the main features of the new device are:
For more information, visit: http://www.agroscan.com/
The practice has also strengthened its surgery services with the appointment of Dr Delphine Holopherne-Doran, European Specialist in Veterinary Anaesthesia and Analgesia.
Ivan graduated from Bristol University in 1997. He worked in Hertfordshire before completing a surgical residency under the tutelage of Professor Peter Holt at Bristol University. Ivan has worked in referral centres in the UK and France. He is an RCVS Diplomate in Small Animal Soft Tissue Surgery and a Recognised Specialist in Small Animal Soft Tissue Surgery. Before joining Highcroft, he spent six years working as a senior staff surgeon at Bristol University.
Ed graduated from the Royal Veterinary College (RVC) in 1996. He worked in a mixed practice in Buckinghamshire before undertaking training positions at the RVC, University of Liverpool and the University of Cambridge. He passed the specialist Diploma examinations of the European College of Veterinary Surgeons in 2003. He has previously been a senior surgeon and member of academic staff at the University of Bristol and has worked in private referral practice.
Delphine graduated from Maisons-Alfort (Paris) Vet School in 1998. After working as an equine vet, where she developed an interest in veterinary anaesthesia and analgesia, she returned to vet school in Nantes where she ran the Anaesthesia department for 11 years. During this time, she gained a Master’s degree and a PhD in cardiovascular pharmacology and completed a residency, gaining European board certification in anaesthesia and analgesia, which led her to visit and train in universities around the world.
Highcroft Hospital Director Mr Chris Mayers said: “Ivan and Ed bring a wealth of experience in urinary tract surgery and, in particular, in urinary incontinence to Highcroft. The most common presentations are juvenile animals with ectopic ureters or urethral sphincter mechanism incompetence (post-spay incontinence). Ivan and Ed offer an innovative, minimally-invasive procedure using cystoscopically-guided laser ablation for patients with intramural ectopic ureters. Interventional radiology techniques are also a major interest for the team providing new, minimally-invasive solutions for intrahepatic shunts. The two surgeons have firmly adopted Subcutaneous Ureteral Bypass Systems (SUBS) in treating cats with ureteral obstruction, typically caused by calculi.
"Delphine adds world-class expertise in anaesthesia and analgesia and is already making a huge contribution to our hospital. With a high degree of skill in managing cardiovascular physiology and pharmacology cases, Delphine boosts our ability to support highly challenging and complex patients. Her knowledge of the use of local and region blocks for treating highly challenging pain cases and the anaesthesia of complex cardiovascular patients provides outstanding care for patients and promotes the highest standard in analgesia."
Highcroft Veterinary Group is based at 615 Wells Road, Whitchurch, Bristol and can be contacted on 01275 832410.
The referral centre recently extended its floor space at its base in Cheshire to support a major expansion of the services being offered, which include orthopaedic, soft tissue and spinal surgery and internal medicine; with specialist support in anaesthesia and pain management, a diabetes clinic, intensive care, cardiology, diagnostic imaging, neurology (medical and surgical) and oncology.
Liz Cousins, hospital manager at Northwest Veterinary Specialists, said: "The success of NWVS is down to the dedication of our highly skilled clinical, nursing and support teams.
"Our clinicians are well respected specialists in their chosen disciplines and it’s fantastic to be able to offer new services to pets and first opinion vets.
"The hospital is home to 88 colleagues and the change of name now reflects the growth and dedication by everyone here at Northwest Veterinary Specialists since opening in 2002."
Northwest Veterinary Specialists provides specialist veterinary services to veterinary practices in north west England and north and mid Wales.
Liz added: "At Northwest Veterinary Specialists we treat pets from as far apart as Carlisle, North Yorkshire and Staffordshire.
"The facilities are state-of-the-art, demonstrating a quality of service both for our clinicians and our clients, but most importantly the pets that we treat."
Based at UCLan’s Preston Campus, the new school will deliver foundation, undergraduate and postgraduate courses in areas such as veterinary medicine, bioveterinary science, veterinary clinical practice, veterinary physiotherapy and rehabilitation, and clinical animal behaviour and training.
Professor Graham Baldwin, UCLan Vice-Chancellor, said: “We’re absolutely delighted to be creating an innovative and dynamic veterinary school. UK veterinary schools are highly prestigious, so we are thrilled to be launching only the second school in the north of England and one of only 11 in the UK.
“We have taken massive strides in developing all areas of human health provision in recent years, and animal health will now join our ever-expanding portfolio of medicine, dentistry, pharmacy, biomedical sciences and optometry.”
Professor Cathy Jackson, Executive Dean of the Faculty of Clinical and Biomedical Sciences, said: “Our new veterinary school will be focussed on producing much needed industry ready graduates for our region, particularly as recent figures have highlighted a national shortage of vets and a sector heavily reliant on vets educated in the European Union.
"As with our medical and dental schools, we have demonstrated we want to break down barriers and make education accessible to all. It’s no different with our veterinary school and we want to open the doors and offer a pathway for any student, no matter of their background, into this rewarding profession, while maintaining the very highest of education and professional standards.”
The Batchelor of Veterinary Medicine and Surgery (BVMS) course at UCLan is a five-year programme with ‘hands-on’ modules from Year 1, rather than in the later years as delivered in more traditional programmes.
UCLan says it is collaborating with Myerscough College for some of its programmes to give students access to state-of-the-art, sector-leading facilities, which have recently benefited from a £35m investment.
In addition, UCLan will become one of the first universities in the world to make use of a digital, virtual dissection platform for teaching animal anatomy using veterinary Anatomage technology.
UCLan is planning to welcome the first intake of UK and international students to veterinary sciences BSc and foundation courses in September 2022 while BVMS students will be welcomed from 2023.
For more information, visit www.uclan.ac.uk/schools/veterinary-medicine.
This latest incarnation of the FECPAKG2 is now a battery-powered and wi-fi enabled. This means it can pair with smartphones, tablets and laptops, allowing samples to be uploaded, analysed and results received, virtually anywhere.
Tabitha Allen from Techion said: "The technology allows internet connected and image-based FEC testing to be carried out literally on the job.
"While the current system is able to return results rapidly, samples need to be uploaded via a computer. The upgrade will therefore give users more flexibility, allowing samples to be processed away from the office."
"Samples are then analysed by trained online technicians so we can confidently provide accurate results, which can then help farmers make informed decisions when it comes to worming.
"The new upgrade now includes a digital microscope that enhances image quality further, making it quicker and easier than ever before to provide these accurate results.
For more information, visit: www.techiongroup.com or ring: 01970 821 918
The centre was launched in February last year after an 8-month briefing and design period, followed by a 9-month construction and fit-out process.
Paragon and DesM also picked up the top prize in the Conversion category, awarded to practices which have made use of buildings previously used for other purposes.
John Marsh said: "Our aim was to build on our experience with two previous small animal hospitals for the RVC and Lower Langford Veterinary School, in designing a 'practitioners' answer' to veterinary care, but adapted to a more commercial facility, mindful of a practical but bright working environment for both the clinicians and owners, where it is a pleasure to work and a catalyst for enabling the best possible animal care."
Paragon managing director Ian Monteith said: "Every year, the BVHA seeks out and rewards the very best veterinary hospitals across the UK and we are delighted the high standards we set here at Paragon have been recognised.
"This is a terrific compliment to the very careful planning that went into designing the building and equipping it with the very latest equipment and technology."
In their report, the BVHA assessor said: "The premises are spectacular in design and appearance, creating an immediate impression of clinical excellence and quality patient care to both clients and visiting clinicians.
"The quality of the clinical work being undertaken was easy to see. There was a very positive attitude to training and induction routines, as well as mental health and team welfare."
There was one other category, for the best refurbishment, which was won by Vets Now’s hospital in Glasgow.
Effipro Duo contains fipronil to kill adult fleas and ticks, and pyriproxyfen, an insect growth regulator, to sterilise adult fleas and inhibit the immature life stages. It provides three months protection against flea life cycle completion.
The product is presented in Effipro’s patented ‘drop-lock’ pipette, designed to ensure that the solution is released only when the owner is ready.
Effipro Duo is offered in packs of 4 pipettes and in a 24-pipette dispensing pack to suit practices offering health plans.
Product Manager Kate Woolley MRCVS said: "Because Effipro Duo targets not just the adult fleas on the pet but also the key developmental stages in the flea life cycle often found in the home, it represents an integrated and easy-to-use solution, both for on-animal flea and tick control and for long-lasting protection of the home environment.
"Household flea infestations are common all year round and experts agree that the combination of an adulticide and an insect growth regulator is the most effective way for owners to protect their homes from this unpleasant problem¹. For complete flea control in the home, we recommend that it is used in conjunction with Indorex®, the UK’s no. 1 household flea spray².
"Virbac offers one of the most extensive parasiticide ranges on the market and we believe Effipro Duo will provide a popular addition, offering owners long-lasting protection from fleas and ticks for their cats and dogs, while helping practices to retain vital parasite control sales in-house."
Mr Roger faced three charges: that he had failed to provide adequate care, failed to communicate with the owner adequately and failed to keep adequate clinical records for Honey, a Shiih Tzu dog who, it transpired, had hypergycaemia.
At the initial consultation, Mr Roger took a blood sample which showed that there was an elevated blood glucose, an elevated white blood cell count, an elevated ALT and an elevated ALP (which Mr Roger took to be indicative of liver damage secondary to infection).
Mr Roger prescribed a cholagogue (ursodeoxycholic acid), an antibiotic (Synulox) and a diuretic (Frusemide).
In its findings of fact, the Committee found it likely that Mr Roger would have realised that Honey had a potential diabetes mellitus diagnosis with an elevated blood glucose of 28.
However, Mr Roger explained that he had believed the elevated blood glucose was due to the stress Honey had undergone in taking the blood samples.
The Committee therefore accepted that Mr Roger’s actions did not indicate a complete failure by him to notice the elevated blood glucose because he had explained he believed at the time it was due to stress.
Honey’s owner took her back to the veterinary practice that Mr Roger worked at three days later.
A different veterinary surgeon examined Honey and flagged that her blood sugar was high and that her liver was damaged.
She was taken to an alternative veterinary practice for follow-up but died later that day.
Mr Roger admitted failing to ask Honey’s owner if there was a history of diabetes mellitus, failing to take repeat blood glucose tests or carry out urine analysis or carry out additional blood tests, failing to communicate adequately with Honey’s owner about the significance of the hyperglycaemia and the options for investigation/management and failing to keep adequate clinical records in regard to Honey’s blood glucose levels.
The Committee found the admitted facts proved.
The evidence presented to the Committee included the clinical notes taken during Honey’s consultations, emails sent from Honey’s owner to the RCVS outlining the complaint, and evidence from experts in small animal veterinary practice.
Although the Committee found some matters not proved, it did find proved that Mr Roger had failed to recognise and/or pay adequate regard to Honey’s elevated blood glucose levels, had failed to manage Honey’s hyperglycaemia either by treating it or by documenting an appropriate plan to do so and had failed to communicate adequately with Honey’s owner about the significance of her elevated glucose and the reason for it.
Having reached its decision in relation to the facts, the Committee went on to consider whether the facts it had found proved either individually or cumulatively amounted to serious professional misconduct.
Judith Way, Chairing the Committee and speaking on its behalf said: “The Committee found that the charges and particulars it had found proved did not amount to disgraceful conduct in a professional respect either individually or cumulatively.
"In its judgment, the conduct found proved fell short of the standard to be expected of a reasonably competent veterinary surgeon but not far short of the standard which is expected of the reasonably competent veterinary surgeon.”
As a result of the Committee finding that Mr Roger was not guilty of serious professional misconduct on any of the proven charges, either individually or in any combination, the hearing did not proceed further.